| tenofovir disoproxil fumarate / Generic mfg. |
NCT00002453: A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection |
|
|
| Completed | N/A | 300 | US | Tenofovir disoproxil fumarate | Gilead Sciences | HIV Infections | | | | |
NCT00011089: Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations |
|
|
| Unknown status | N/A | | US | Tenofovir disoproxil fumarate | Gilead Sciences | HIV Infections | | | | |
NCT00016588: Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs |
|
|
| Completed | N/A | | US | Tenofovir disoproxil fumarate | Gilead Sciences | HIV Infections | | | | |
NCT00028366: Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People |
|
|
| Completed | N/A | 56 | US | Fosamprenavir, Lopinavir/Ritonavir, Ritonavir, Tenofovir disoproxil fumarate | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | 07/05 | | |
| Completed | N/A | 22 | US | Lopinavir/Ritonavir, Lamivudine/Zidovudine, Tenofovir disoproxil fumarate, Pneumococcal Vaccine, Polyvalent (23-valent), Lamivudine, Stavudine, Zidovudine, Didanosine, Lyme Disease Vaccine Recombinant OspA, Haemophilus B Conjugate Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | | 06/06 | | |
HADIT, NCT00344981: Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression |
|
|
| Completed | N/A | 9 | US | Tenofovir, Viread, Hydroxyurea, Hydrea | University of Maryland, Baltimore | HIV Infections, AIDS | 11/06 | 11/06 | | |
NCT00100581: Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults |
|
|
| Completed | N/A | 2 | US | Efavirenz, Lamivudine, Lopinavir/ritonavir, Pegylated interferon alfa-2a, Ribavirin, Tenofovir disoproxil fumarate | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections, Hepatitis C | | 01/07 | | |
NCT00109603: Effect of Tenofovir Disoproxil Fumarate on Lipid Levels in HIV Infected Adults on Stable Anti-HIV Drug Therapy |
|
|
| Completed | N/A | 17 | US | Tenofovir disoproxil fumarate | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections, Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hypertriglyceridemia | 07/07 | 11/07 | | |
NCT00051831: Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults |
|
|
| Completed | N/A | 19 | US | Emtricitabine, FTC, Emtriva, Enfuvirtide, ENF, Fuzeon, T-20, Ritonavir, RTV, Norvir, Saquinavir, Invirase, Saquinavir mesylate, Tenofovir disoproxil fumarate, TDF, Viread | National Institute of Allergy and Infectious Diseases (NIAID), AIDS Clinical Trials Group | HIV Infections | 12/07 | 05/08 | | |
NCT00312169: Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA) |
|
|
| Completed | N/A | 20 | US | | Orlando Immunology Center, GlaxoSmithKline | HIV Infections | 05/08 | 05/08 | | |
NCT01361165: Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism |
|
|
| Completed | N/A | 10 | US | | National Cancer Institute (NCI) | HIV-Infected Children | | 10/08 | | |
| Completed | N/A | 180 | US | Vicriviroc maleate, SCH 417690, Placebo, Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg, Truvada | Merck Sharp & Dohme LLC | HIV Infections | 09/10 | 09/10 | | |
| Completed | N/A | 11 | US | ARV regimen chosen by treating physician, Zidovudine: ZDV, Retrovir, Retrovis, AZT (Azidothymidine), Lamivudine: 3TC, Zeffix, Epivir, Epivir-HBV, Emtricitabine: FTC, Emtriva, Abacivir: Ziagen, Tenofovir: TDF, Viread, Efavirenz: Sustiva, Stocrin, Lopinavir/Ritonavir: Kaletra, Aluvia, Atazanavir: Reyataz, Ritonavir: Norvir, Maraviroc: Selzentry, Raltegravir: MK-0518, Isentress, Etravirine: TMC-125, Intelence | Kristine Patterson, MD, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 05/12 | 05/12 | | |
NCT01293123: Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals |
|
|
| Terminated | N/A | 2 | US | Raltegravir, tenofovir disoproxil fumarate 300 mg PO once daily, emtricitabine 200 mg PO once daily, Efavirenz | University of California, San Diego, Merck Sharp & Dohme LLC | HIV | 06/13 | 12/13 | | |
NCT00977756: IMPAACT P1058A: Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults |
|
|
| Completed | N/A | 168 | US | Raltegravir (RAL), Isentress, Atazanavir (ATV), Reyataz, Ritonavir (RTV), Norvir, Tenofovir (TDF), Viread, Etravirine (ETV), Intelence, Darunavir (DRV), Prezista, Maraviroc (MVC), Selzentry, Lopinavir/ritonavir (LPV/r), Kaletra | International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 03/14 | 03/14 | | |
| Completed | N/A | 229 | NA | Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Truvada | Centers for Disease Control and Prevention, Botswana Ministry of Health | HIV Infections | 07/14 | 07/14 | | |
NCT01066858: Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding |
|
|
| Completed | N/A | 1765 | RoW | Tenofovir disoproxil fumarate (TDF) | National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Gilead Sciences | HIV Infections | 11/15 | 11/15 | | |
NCT02827643: Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz |
|
|
| Unknown status | N/A | 48 | RoW | TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement, ergocalciferol, TDF/3TC or FTC/EFV | Mahidol University | Bone Density | 03/17 | 06/17 | | |
NCT03377608: Modifiers of Tenofovir in the Female Genital Tract |
|
|
| Completed | N/A | 50 | RoW | Tenofovir Disoproxil Fumarate, Depo-Provera | University of Minnesota, MU-JHU CARE | HIV/AIDS, Contraception | 03/18 | 04/18 | | |
| Completed | N/A | 194 | RoW | Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg, Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg, Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily | Obafemi Awolowo University, Federal Medical Centre, Makurdi, University of Liverpool, University of California, San Diego, London School of Hygiene and Tropical Medicine | Human Immunodeficiency Virus Infection | 12/19 | 09/20 | | |
| Terminated | N/A | 152 | RoW | HIV-2 Genotypic Drug Resistance Testing using DBS, 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID ), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID) | University of Washington, Clinique des Maladies Infectieuses, CHNU de Fann, Dakar, Senegal, Centre de Sante de Ziguinchor, Casamance, Senegal, Janssen Pharmaceutica, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID) | HIV-2 Infection | 05/20 | 05/20 | | |
| Completed | N/A | 200 | RoW | Tenofovir Disoproxil Fumarate (TDF) 300 mg, Lamivudine (3TC) 300mg | Myanmar Oxford Clinical Research Unit, Medical Action Myanmar, Institute of Tropical Medicine, Belgium | HIV Infections | 08/21 | 08/21 | | |
NCT04583267: HIV Pre-exposure Prophylaxis Implementation Study in South Korea |
|
|
| Recruiting | N/A | 200 | RoW | tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration | Yonsei University | HIV Infections | 12/22 | 12/22 | | |
NCT04367688: HIV Pre-exposure Prophylaxis Implementation Hong Kong Study |
|
|
| Completed | N/A | 339 | RoW | Tenofovir Disoproxil Fumarate 300 mg / emtricitabine 200 mg | Chinese University of Hong Kong | HIV Infections | 09/23 | 01/24 | | |
NCT05996094: Antiretroviral Adherence and Drug-level Monitoring |
|
|
| Recruiting | N/A | 100 | RoW | | Zamrotul Izzah, Universitas Airlangga | HIV Infections, AIDS, Antiretroviral Therapy, Highly Active, Adherence, Medication, Drug-level Monitoring | 12/23 | 12/23 | | |
| Enrolling by invitation | N/A | 500 | Europe | Tenofovir Disoproxil Fumarate 300 MG Oral Tablet, Emtricitabine 200 MG Oral Tablet | Hospitales Universitarios Virgen del Rocío, Instituto de Biomedicina de Sevilla | HIV Infection Primary, Hepatitis, Viral, Human, Sexually Transmitted Infections, Excluding HIV and Hepatitis | 12/29 | 12/30 | | |
